Bank of America’s BioLineRX BLRX Stock Holding History

Bank of America’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10	Closed	-$28	–	5846
2025 Q4	$28	Buy	10 +8	+400%	+$28	﹤0.01%	7057
2025 Q3	$8	Hold	2	–	–	﹤0.01%	8229
2025 Q2	$9	Hold	2	–	–	﹤0.01%	8301
2025 Q1	$6	Buy	+2	New	+$8	﹤0.01%	8231
2017 Q4	–	Sell	-27	Closed	-$18K	–	7028
2017 Q3	$18K	Hold	27	–	–	﹤0.01%	6309
2017 Q2	$14K	Hold	27	–	–	﹤0.01%	6323
2017 Q1	$16K	Hold	27	–	–	﹤0.01%	6388
2016 Q4	$15K	Hold	27	–	–	﹤0.01%	6442
2016 Q3	$19K	Hold	27	–	–	﹤0.01%	6141
2016 Q2	$13K	Hold	27	–	–	﹤0.01%	6408
2016 Q1	$17K	Buy	+27	New	+$17K	﹤0.01%	6196

Other funds holding BLRX

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America's BLRX Position: Q1 2026 in Review

Bank of America sold out of BioLineRX (BLRX) in Q1 2026, closing a stake of 10 shares — an estimated $28 sold.

Bank of America first reported a position in BLRX in Q1 2016 and held it in 11 quarters. The position peaked at $19K in Q3 2016. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

Bank of America reported no remaining BioLineRX position as of Q1 2026 after selling out during the quarter.
Bank of America sold 10 BioLineRX shares in Q1 2026, an estimated $28.
Bank of America first reported a position in BioLineRX in Q1 2016 and held it in 11 quarters.
Bank of America's BioLineRX position peaked at $19K in Q3 2016.
13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.